273 related articles for article (PubMed ID: 16818139)
1. Malignancy in pediatric transplant recipients.
Buell JF; Gross TG; Thomas MJ; Neff G; Muthiah C; Alloway R; Ryckman FC; Tiao GM; Woodle ES
Semin Pediatr Surg; 2006 Aug; 15(3):179-87. PubMed ID: 16818139
[TBL] [Abstract][Full Text] [Related]
2. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
3. Posttransplant lymphoproliferative disorder.
Everly MJ; Bloom RD; Tsai DE; Trofe J
Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
Mendoza F; Kunitake H; Laks H; Odim J
Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
6. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
7. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
Lim WH; Russ GR; Coates PT
Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
Taylor AL; Marcus R; Bradley JA
Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
[TBL] [Abstract][Full Text] [Related]
9. Posttransplant lymphoproliferative diseases.
Gross TG; Savoldo B; Punnett A
Pediatr Clin North Am; 2010 Apr; 57(2):481-503, table of contents. PubMed ID: 20371048
[TBL] [Abstract][Full Text] [Related]
10. Development of lymphoproliferative disease after liver transplantation.
Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
[TBL] [Abstract][Full Text] [Related]
11. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients.
Libertiny G; Watson CJ; Gray DW; Welsh KI; Morris PJ
Br J Surg; 2001 Oct; 88(10):1330-4. PubMed ID: 11578286
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.
Gallego S; Llort A; Gros L; Sanchez de Toledo J; Bueno J; Moreno A; Nieto J; Sanchez de Toledo J
Pediatr Transplant; 2010 Feb; 14(1):61-6. PubMed ID: 19344338
[TBL] [Abstract][Full Text] [Related]
13. Malignancy after solid organ transplantation: an overview.
Zafar SY; Howell DN; Gockerman JP
Oncologist; 2008 Jul; 13(7):769-78. PubMed ID: 18614590
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
Svoboda J; Kotloff R; Tsai DE
Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
[TBL] [Abstract][Full Text] [Related]
15. De novo malignances in pediatric organ transplant recipients.
Penn I
Pediatr Transplant; 1998 Feb; 2(1):56-63. PubMed ID: 10084762
[TBL] [Abstract][Full Text] [Related]
16. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ
Transpl Int; 2007 Mar; 20(3):207-18. PubMed ID: 17291214
[TBL] [Abstract][Full Text] [Related]
17. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
[TBL] [Abstract][Full Text] [Related]
18. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
[TBL] [Abstract][Full Text] [Related]
19. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
Quintini C; Kato T; Gaynor JJ; Ueno T; Selvaggi G; Gordon P; McLaughlin G; Tompson J; Ruiz P; Tzakis A
Transplant Proc; 2006; 38(6):1755-8. PubMed ID: 16908272
[TBL] [Abstract][Full Text] [Related]
20. Controlling the incidence of infection and malignancy by modifying immunosuppression.
Soulillou JP; Giral M
Transplantation; 2001 Dec; 72(12 Suppl):S89-93. PubMed ID: 11833147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
